1 / 4

Effects of Fenofibrate on Lipid Profiles, Angiographic Changes, and Clinical Endpoints in CAD Patients

This study analyzes the baseline lipid characteristics, mean lipid changes, angiographic changes, and combined clinical endpoints in patients with CAD treated with fenofibrate compared to a placebo. The findings show significant reductions in total cholesterol (TC), triglycerides (TG), LDL-C, and increases in HDL-C levels. Angiographic changes also demonstrated improvements in CAD measures, although clinical event rates showed a non-significant decrease in the fenofibrate group. Published in Lancet 2001, this study provides insight into the lipid-modifying effects and potential benefits of fenofibrate in CAD management.

thane-gay
Télécharger la présentation

Effects of Fenofibrate on Lipid Profiles, Angiographic Changes, and Clinical Endpoints in CAD Patients

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chol TG 232 531 354 155 177 77 0 0 DAIS: Baseline Lipid Characteristics mg/dL Placebo Fenofibrate p = 0.033 TC TG LDL-C HDL-C mean + SD DAIS Investigators. Lancet 2001;357:905-910.

  2. DAIS: Mean Lipid Changes 10 0 -10 -20 -30 Percent Change Placebo Fenofibrate TC LDL-C HDL-C TG DAIS Investigators. Lancet 2001;357:905-910. Reprinted with permission from Elsevier Science.

  3. DAIS: Angiographic Changes from Baseline % change p = 0.029 p = 0.020 p = 0.171 mm mm 4.00 2.00 0.00 -0.10 -0.08 -0.06 -0.04 -0.02 0.00 -0.10 -0.08 -0.06 -0.04 -0.02 0.00 -40% -25% -42% Progression of CAD Minimum lumen diameter Percent Stenosis Mean Segment Diameter DAIS Investigators. Lancet 2001;357:905-910.

  4. DAIS: Combined Clinical Endpoints 25 20 15 10 5 0 Placebo -23%* Fenofibrate *DAIS was not powered to examine clinical events. Even though the results suggest a trend, they were not statistically significant Event Rate 50 38 * Number of participants with at least one clinical or interventional endpoint, including death, stroke, MI, CABG, PTCA and hospitalization for angina DAIS Investigators. Lancet 2001;357:905-910.

More Related